info@Selagine.com
312-526-3725
News
Topical Biologics In Ophthalmology?
Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease
Grifols enters into global collaboration and licensing agreement with Selagine to develop immunoglobulin eye drops to treat dry eye disease
Dry eye disease: New treatment on the horizon
Antibody-based eye drops show promise for treating dry eye disease
Scientific Publications
Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease
Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops (“Triple Play”) in Recalcitrant Immunological Ocular Surface Diseases
SELAGINE Inc, 2315 W Taylor St, Ste A, Chicago, IL 60612
@ Copyright 2023 SELAGINE INC | Privacy Statement
